Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 7.01, 9.01 · 8-K

60 Degrees Pharmaceuticals, Inc.

SXTPNASDAQEQUITYCurrent

Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On October 23, 2026, the Company updated its investor presentation, which it intends to use from time to time in meetings with investors, analysts and other members of the investment community. A copy of the updated investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.…

Filed Oct 23, 2026Accepted Oct 23, 2026, 8:00 AM EDTCIK 1946563Accession 0001213900-26-111864
Share

Company context

60 Degrees Pharmaceuticals, Inc., founded in 2010, develops and commercializes new medicines for the treatment and prevention of vector-borne disease. The Company won U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018 and currently has 3 active clinical trials underway for babesiosis, an emerging tick-borne disease. ARAKODA is sold commercially in the U.S. and Australia. 60 Degrees also collaborates with prominent research and academic organizations in the U.S. and Australia to advance science around vector-borne disease. The Company is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.

Current securities

Recent company filings

  1. Other EventsOct 27, 2026
  2. Regulation FD Disclosure · Other EventsOct 6, 2026
  3. Other EventsSep 14, 2026
  4. Regulation FD DisclosureSep 8, 2026
  5. EFFECT filingAug 25, 2026

Registered securities in this filing

60 DEGREES PHARMACEUTICALS, INC. · 8-K · Filed 2026-10-23

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001 per share

Symbol
SXTP
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: From2026-10-232026-10-23_custom_CommonStockParValue0.0001PerShareMember

Dimensions: us-gaap:StatementClassOfStockAxis

Warrants, each warrant to purchase one share of Common Stock

Symbol
SXTPW
Exchange
NASDAQ
Classification
WARRANT
Status
Current
Filing context

Context: From2026-10-232026-10-23_custom_WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000121390026111864 · 2 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On October 23, 2026, the Company updated its investor presentation, which it intends to use from time to time in meetings with investors, analysts and other members of the investment community. A copy of the updated investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing. Cautionary Statement Regarding Forward-Looking Statements This Current Report on Form 8-K includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause the Company’s actual results and financial position to differ materially. These risks and uncertainties include uncertainties associated with market conditions and other risks described under the heading “Risk Factors” in the Company’s SEC Filings on Form 10-K and Form 10-Q. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date hereof.
Filed exhibits (1)
EX-99.1 (by filename) ea030933901ex99-1.htm

Exhibit 99.1 Tafenoquine for Babesiosis Progress across acute, relapsing and chronic disease Geoffrey S. Dow, PhD Chief Executive Officer 2026 ILADS Annual Scientific Conference October 22 - 25, 2026 | Herndon, Virginia Reframing Complex Disease: Pathways to Treatment 2026 update A marketed antimalarial platform now has converging evidence across three clinical settings. CHRONIC DIAGNOSTICS RELAPSING DISEASE HOSPITAL READOUT Regulatory objective A potential sNDA in 2027 - and a request for national-priority review. 60° PHARMA ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 1 Disclaimer and Forward-Looking Statements DISCLAIMER. The information contained herein has been prepared to assist prospective investors in making their own evaluation of 60 Degrees Pharmaceuticals, Inc. (the "Company") and does not purport to be all-inclusive or to contain all of the information a prospective or existing investor may desire. In all cases, interested parties will be expected to have conducted their own due diligence investigation regarding these and all other matters pertinent to investment in the Company. The Company makes no representation or warranty as to the accu…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.